Core Viewpoint - Merck & Co., Inc. is seen as undervalued by the market due to concerns over the upcoming patent expiration of Keytruda, but analysts believe there is a clear path for the company to manage this transition and continue to grow [2][3]. Group 1: Analyst Upgrades and Price Target - Deutsche Bank analyst James Shin upgraded Merck from Hold to Buy and raised the price target from $115 to $150, indicating confidence in the company's future despite patent concerns [2]. - The analyst's note suggests that the market is not fully recognizing Merck's potential growth drivers beyond Keytruda [2]. Group 2: Financial Forecasts and Challenges - Merck expects 2026 revenue to be between $65.5 billion and $67.0 billion, which is below the average analyst estimate of $67.6 billion [3]. - The company anticipates a $2.5 billion headwind in 2023 due to generic competition, Medicare price negotiations, and reduced sales of its COVID-19 treatment, Lagevrio [3]. - CEO Rob Davis highlighted that legacy products, particularly Januvia and related treatments, may underperform compared to analyst expectations due to their impending patent expirations [3]. Group 3: Company Overview - Merck operates as a global healthcare company, focusing on prescription medicines, biologic therapies, vaccines, and animal health products, with a significant emphasis on human health treatments [4].

Core Insights - Merck & Co. (MRK) and Bristol Myers Squibb (BMY) are significant players in the pharmaceutical industry with diverse product portfolios [1][2] - Merck is recognized for its leadership in oncology, while Bristol Myers focuses on breakthrough therapies across multiple therapeutic areas [1][2] Merck (MRK) Overview - Merck has over six blockbuster drugs, with Keytruda accounting for 54% of total sales in 2025, driving revenue growth [3][4] - Keytruda's sales increased by approximately 7% in 2025, benefiting from its approval for various oncology indications [4] - The FDA approved Keytruda Qlex for subcutaneous administration in September 2025, with peak sales targeted at $35 billion by 2028 [5] - Other oncology drugs like Welireg, Lynparza, and Lenvima are contributing to growth, alongside a strong launch of Winrevair in pulmonary arterial hypertension [6] - Merck is enhancing its vaccine portfolio, particularly with the new 21-valent pneumococcal conjugate vaccine, Capvaxive [7] - The company has around 80 ongoing late-stage studies, expecting over $70 billion in potential commercial opportunities by the mid-2030s [8] Bristol Myers Squibb (BMY) Overview - BMY's growth portfolio includes key brands such as Opdivo, Yervoy, and Reblozyl, with a strong oncology focus [12] - Opdivo's consistent label expansion has maintained its momentum, and the approval of Opdivo Qvantig has strengthened its franchise [13] - BMY's Reblozyl sales exceed $2 billion annually, and strong performance in cardiovascular drug Camzyos has boosted revenues [14] - However, legacy drugs face significant generic competition, with expected sales declines of 12-16% in 2026 [15] - BMY is pursuing strategic acquisitions and collaborations, including a recent agreement with BioNTech to co-develop a bispecific antibody [16][17] - The company aims for $2 billion in annualized cost savings by the end of 2027, having achieved approximately $1 billion in savings in 2025 [18] Financial Performance and Valuation - MRK's 2026 sales are estimated to increase by 2.59%, but EPS is expected to decline by 38.75% [20] - BMY's 2026 sales are projected to decrease by 2.32%, while EPS is expected to increase by 0.33% [20] - MRK shares trade at 21X forward earnings, while BMY trades at 9.74X, with the industry average at 18.74X [24] - BMY offers a higher dividend yield of 4.22% compared to MRK's 2.79% [25] Investment Outlook - BMY is currently viewed as a stronger near-term investment option compared to MRK, which faces multiple headwinds [9][30] - BMY's strategic initiatives and new drug approvals position it favorably against MRK's challenges, including declining sales of Gardasil and competitive pressures on Keytruda [27][30]

Core Insights - Merck's stock has increased by 7.4% over the past month, driven by better-than-expected fourth-quarter results and a positive outlook for future growth [1][10] - The company reported fourth-quarter earnings of $2.04 per share, a 19% year-over-year increase, and sales of $16.40 billion, up 5% [1] - Merck's 2026 revenue outlook is projected between $65.5 billion and $67.0 billion, reflecting a year-over-year growth of 1% to 3%, but adjusted EPS is expected to decline significantly due to higher business development charges [2] Financial Performance - In Q4, Merck's earnings and sales exceeded estimates, contributing to the stock's rise [1][10] - The company anticipates a decline in adjusted EPS from $8.98 in 2025 to between $5.00 and $5.15 in 2026 [2] - Merck's stock has outperformed the industry, rising 43.6% in the past year compared to the industry's 19.1% increase [24][25] Product Portfolio and Pipeline - Keytruda remains a significant driver for Merck, accounting for approximately 55% of pharmaceutical sales, with sales of $31.7 billion in 2025, a 7% increase year-over-year [5][6] - The company expects Keytruda to achieve peak sales of $35 billion by 2028, despite the impending loss of patent exclusivity [8] - Merck's pipeline has expanded significantly, with new products like Capvaxive and Winrevair showing potential for substantial revenue generation [11][12] Strategic Initiatives - Merck is pursuing innovative strategies to enhance Keytruda's long-term growth, including new immuno-oncology combinations and partnerships for personalized cancer vaccines [7] - The company has been active in acquisitions to bolster its pipeline, including the purchase of Verona and Cidara Therapeutics, which added promising candidates to its portfolio [14][15] - Merck's Animal Health business is projected to contribute significantly to revenue growth, with expectations of doubling sales by the mid-2030s [32] Challenges and Market Dynamics - Sales of Gardasil, Merck's HPV vaccine, have declined due to weak demand in China, with a 39% drop in 2025 [16] - The company faces increasing competition for Keytruda from new dual PD-1/VEGF inhibitors, which may impact its market position [19][20] - Merck anticipates a revenue hit of approximately $2.5 billion in 2026 due to generic competition affecting several of its products [22][23]

Core Insights - Merck's financial performance for 2025 shows steady growth driven by Keytruda, new products like Winrevair and Capvaxive, and stable animal health business, with total sales reaching $65 billion, a 1% year-over-year increase [1] - The company projects 2026 sales between $65.5 billion and $67 billion, with adjusted EPS expected to be between $5.00 and $5.15, both below Wall Street expectations [1][6] - A significant one-time expense from the acquisition of Cidara Therapeutics is expected to impact 2026 adjusted EPS, which includes approximately $3.65 per share related to this acquisition [1][6] Financial Performance - For Q4 2025, sales were $16.4 billion, a 4% increase from Q4 2024, while total sales for the year were $65.011 billion, up 1% [2] - Non-GAAP EPS for 2025 was $8.98, reflecting a 17% increase year-over-year, while GAAP EPS was $7.28, an 8% increase [2] Product Performance - Gardasil sales faced significant challenges, with Q4 sales at $1.031 billion, a 35% decline year-over-year, and annual sales down 39% to $5.233 billion [3] - Keytruda sales reached $8.4 billion in Q4, a 7% increase, with annual sales surpassing $30 billion for the first time, totaling $31.68 billion [4] - New products like Winrevair and Capvaxive showed strong performance, with Winrevair achieving $1.443 billion in annual sales, and Capvaxive reaching $759 million [5] Strategic Outlook - Merck is focusing on product portfolio transformation to mitigate the impact of patent expirations and competition, with strategic acquisitions being a key part of this strategy [5] - The company has identified potential acquisition opportunities valued in the billions to drive future growth [4] 2026 Guidance - The 2026 guidance includes significant one-time costs from the Cidara acquisition, with adjusted EPS expected to be impacted by these costs [6][7] - The company anticipates a gross margin of approximately 82% for 2026, with adjusted operating expenses projected between $35.9 billion and $36.9 billion [7]

Core Insights - Merck reported $16.4 billion in revenue for Q4 2025, a 5% year-over-year increase, with an EPS of $2.04 compared to $1.72 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] Financial Performance - Revenue surprise was +1.33% over the Zacks Consensus Estimate of $16.19 billion, while the EPS surprise was +0.62% over the consensus estimate of $2.03 [1] - Merck's shares returned +5.5% over the past month, outperforming the Zacks S&P 500 composite's +1.8% change [3] Key Product Sales - Hospital Acute Care (Bridion) in the U.S. generated $451 million, exceeding the estimated $418.39 million, reflecting an 18.1% year-over-year increase [4] - Oncology (Keytruda) international sales reached $3.45 billion, surpassing the $3.39 billion estimate, with a 15% year-over-year increase [4] - Diabetes (Janumet) in the U.S. reported $57 million, below the estimated $69.57 million, marking a significant decline of 37.4% year-over-year [4] - Oncology (Lynparza) alliance revenue in the U.S. was $180 million, slightly above the $176.62 million estimate, with a 1.7% year-over-year increase [4] - Cardiovascular (Winrevair) sales were $467 million, exceeding the estimated $452.86 million [4] - Vaccines (Vaxneuvance) generated $140 million, below the $178.52 million estimate, reflecting a 13% year-over-year decline [4] - Oncology (Welireg) sales reached $220 million, surpassing the $195.53 million estimate [4] - Oncology (Keytruda) domestic sales were $8.34 billion, slightly above the $8.31 billion estimate, with a 6.4% year-over-year increase [4] - Oncology (Lenvima) alliance revenue was $272 million, exceeding the $243.71 million estimate, with a 6.7% year-over-year increase [4] - Vaccines (Gardasil) reported $1.03 billion, close to the $1.04 billion estimate, but down 33.5% year-over-year [4] - Virology (Lagevrio) sales were $57 million, above the $45.95 million estimate, but down 52.9% year-over-year [4] - Oncology (Reblozyl) alliance revenue was $164 million, exceeding the $138.97 million estimate, with a significant 49.1% year-over-year increase [4]

Core Viewpoint - Merck reported strong fourth-quarter earnings driven by demand for its cancer immunotherapy Keytruda, but provided a modest 2026 outlook that fell short of Wall Street expectations due to upcoming patent expirations and generic competition [1][2]. Financial Performance - For the fourth quarter, Merck posted net income of $2.96 billion, or $1.19 per share, compared to $3.74 billion, or $1.48 per share, in the same period last year [4]. - Adjusted earnings for the fourth quarter were $2.04 per share, slightly above the expected $2.01 per share [6]. - Revenue for the quarter was $16.4 billion, a 5% increase from the previous year, and exceeded expectations of $16.19 billion [5][6]. 2026 Outlook - Merck anticipates 2026 revenue between $65.5 billion and $67 billion, lower than analysts' expectations of $67.6 billion [2]. - The company expects adjusted earnings per share to be between $5 and $5.15, compared to the analyst estimate of $5.36 [2]. Acquisition and Charges - The 2026 guidance includes a one-time charge of approximately $9 billion, or around $3.65 per share, related to the acquisition of Cidara, which is developing a flu prevention drug [3]. Cost Management - Merck is implementing a cost-cutting plan aimed at reducing expenses by $3 billion by the end of 2027 to offset revenue losses from the upcoming patent expiration of Keytruda in 2028 [5]. Drug Pricing Deal - Under a "most favored nation" deal, Merck will sell existing treatments to Medicaid patients at the lowest price offered in other developed nations and will receive a three-year reprieve from tariffs [4].

Core Viewpoint - Merck (MRK) is expected to report quarterly earnings of $2.04 per share, an 18.6% increase year-over-year, with revenues projected at $16.19 billion, reflecting a 3.6% increase compared to the same period last year [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been revised downward by 85.2%, indicating a significant reassessment by analysts [2]. - Revisions to earnings estimates are crucial for predicting investor actions, as empirical research shows a strong correlation between earnings estimate trends and short-term stock performance [3]. Key Metrics Projections - Analysts estimate 'Sales- Vaccines- Vaxneuvance' at $178.52 million, a 10.9% increase year-over-year [5]. - 'Sales- Oncology- Keytruda' is projected to reach $8.31 billion, reflecting a 6.1% increase from the previous year [5]. - 'Sales- Oncology- Alliance revenue- Lenvima' is expected to be $243.71 million, indicating a 4.4% decrease year-over-year [5]. Additional Sales Estimates - 'Sales- Vaccines- Gardasil' is projected at $1.04 billion, showing a significant decline of 32.9% year-over-year [6]. - 'Sales- Hospital Acute Care- Bridion - U.S.' is expected to reach $418.39 million, a 9.5% increase year-over-year [6]. - 'Sales- Oncology- Keytruda - International' is estimated at $3.39 billion, reflecting a 13.3% increase year-over-year [6]. Further Sales Insights - 'Sales- Diabetes- Janumet - U.S.' is forecasted at $69.57 million, a decrease of 23.6% year-over-year [7]. - 'Sales- Oncology- Alliance revenue- Lynparza - U.S.' is expected to be $176.62 million, showing a slight decrease of 0.2% [7]. - 'Sales- Oncology- Alliance revenue- Lynparza - International' is projected at $211.75 million, indicating a 13.2% increase year-over-year [8]. Market Performance - Merck shares have recorded a return of +1.6% over the past month, outperforming the Zacks S&P 500 composite's +0.8% change [9]. - Based on its Zacks Rank 4 (Sell), Merck is expected to underperform the overall market in the upcoming period [10].

Core Insights - Merck reported revenue of $17.28 billion for the quarter ended September 2025, reflecting a 3.7% increase year-over-year and a surprise of +1.24% over the Zacks Consensus Estimate of $17.06 billion [1] - Earnings per share (EPS) for the quarter was $2.58, compared to $1.57 in the same quarter last year, resulting in a surprise of +9.32% over the consensus estimate of $2.36 [1] Financial Performance - Hospital Acute Care sales for Bridion in the U.S. reached $392 million, exceeding the estimated $379.07 million, marking a +15.6% change year-over-year [4] - Oncology sales for Keytruda internationally were $3.26 billion, slightly below the estimated $3.33 billion, with a year-over-year increase of +11.4% [4] - Sales for Diabetes drug Janumet in the U.S. were $78 million, significantly surpassing the estimated $42.82 million, representing a +420% change year-over-year [4] - Alliance revenue for Lynparza in the U.S. was $184 million, exceeding the estimated $156.52 million, with a +14.3% year-over-year change [4] - Animal health sales totaled $1.62 billion, above the estimated $1.56 billion, reflecting an +8.6% change year-over-year [4] - Cardiovascular sales for Winrevair were $360 million, below the estimated $426.29 million [4] - Oncology sales for Keytruda were $8.14 billion, slightly below the estimated $8.4 billion, with a +9.6% year-over-year change [4] - Sales for Virology drug Lagevrio were $138 million, below the estimated $144.08 million, representing a -64% year-over-year change [4] - Sales for Gardasil vaccines were $1.75 billion, matching the average estimate, but reflecting a -24.2% year-over-year change [4] - Alliance revenue for Lenvima was $258 million, exceeding the estimated $242.44 million, with a +2.8% year-over-year change [4] Stock Performance - Merck's shares have returned -3.9% over the past month, contrasting with the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Merck reported revenue of $15.53 billion for Q1 2025, a decrease of 1.6% year-over-year, with an EPS of $2.22, up from $2.07 in the same quarter last year, exceeding both revenue and EPS consensus estimates [1][2] Financial Performance - Revenue of $15.53 billion compared to Zacks Consensus Estimate of $15.39 billion, resulting in a surprise of +0.93% [1] - EPS of $2.22 compared to consensus estimate of $2.15, leading to an EPS surprise of +3.26% [1] Key Metrics - Merck's stock has returned -10.6% over the past month, underperforming the Zacks S&P 500 composite's -5.1% change [3] - Current Zacks Rank for Merck is 3 (Hold), indicating potential performance in line with the broader market [3] Oncology Sales - Keytruda U.S. sales were $4.31 billion, below the average estimate of $4.47 billion, but up 4.6% year-over-year [4] - Keytruda International sales were $2.90 billion, compared to the $3.08 billion estimate, reflecting a 2.4% year-over-year increase [4] - Lynparza U.S. sales reached $145 million, exceeding the $121.96 million estimate, with a year-over-year increase of 7.4% [4] - Lynparza International sales were $168 million, below the $178.66 million estimate, but up 7% year-over-year [4] - Total Keytruda sales amounted to $7.21 billion, compared to the $7.55 billion estimate, marking a 3.7% year-over-year increase [4] Other Product Sales - Zerbaxa sales in Hospital Acute Care were $70 million, surpassing the $63.07 million estimate, with a 25% year-over-year increase [4] - Animal health sales were $1.59 billion, slightly below the $1.61 billion estimate, but up 5.1% year-over-year [4] - Prevymis sales were $208 million, exceeding the $190.69 million estimate, with a significant year-over-year increase of 19.5% [4] - Reblozyl sales reached $119 million, above the $101.77 million estimate, reflecting a substantial year-over-year increase of 67.6% [4]